Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Last trade$4.23
Day change-$0.07 (-1.63%)
Day range$4.21 – $4.37
Volume2,319,526
Market cap$1.54B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.54B
Price / earnings
63.17×
Price / book
18.4×
Price / sales
9.82×
EV / sales
10.33×
EV / EBITDA
42.57×
Profitability
Earnings per share
$0.07
Return on assets
11.51%
Return on equity
29.12%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.12×
Current ratio
5.58×
Quick ratio
4.83×
Cash ratio
0.49×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$74.32M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PGEN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$74.15M
$54.98M
$23.25M
$4.57M
$2.92M
$856K
$1.34M
$1.19M
Cost of revenue
$6.51M
$2.81M
$2.56M
$1.6M
$1.04M
$1.09M
$1.1M
$1.17M
Gross profit
$67.64M
$52.17M
$20.69M
$2.97M
$1.89M
-$236K
$241K
$21K
Selling, general and administrative
$22.36M
$22.25M
$21.05M
$17.65M
$23.99M
$16.13M
$12.36M
$11M
Research and development
$6.63M
$7.28M
$5.64M
$6.99M
$12.38M
$11.49M
$10.48M
$11.76M
Total operating expenses
$28.99M
$29.53M
$26.69M
$24.64M
$36.37M
$31.53M
$22.84M
$28.54M
Operating income
$38.65M
$22.64M
-$5.99M
-$21.67M
-$34.48M
-$31.76M
-$22.6M
-$28.52M
Interest expense
-$3M
-$2.95M
-$2.91M
-$2.96M
-$902K
$0
-$1K
$0
Income before taxes
$35.97M
$20.07M
-$7.93M
-$23.5M
-$146.34M
-$26.64M
-$54.15M
-$19.81M
Income taxes
$200K
$0
$0
$0
$0
$3K
$0
-$87K
Net income
$35.77M
$20.07M
-$7.93M
-$23.5M
-$146.34M
-$26.64M
-$54.15M
-$19.73M
Net income attributable to common shareholders
$35.77M
$20.07M
-$7.93M
-$23.5M
-$325.34M
-$26.64M
-$54.15M
-$19.73M
EBITDA
$39.76M
$23.74M
-$4.9M
-$20.53M
-$33.68M
-$27.23M
-$21.97M
-$22.08M
Basic earnings per share
$0.10
$0.06
-$0.02
-$0.07
-$1.06
-$0.09
-$0.18
-$0.07
Diluted earnings per share
$0.08
$0.05
-$0.02
-$0.07
-$1.06
-$0.09
-$0.18
-$0.07
Recent news
Company coverage with links to the original publishers.
Precigen, Inc. (PGEN) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 remains at $0.27 per share, but analysts have raised estimates by 6.7% over the past three months. The upgrade positions PGEN in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation.
Precigen (PGEN) reported Q3 2026 revenues of $74.15M, slightly missing consensus estimates, with PAPZIMEOS generating $72.9M in net revenue, up 37% sequentially. The company treated over 500 patients and achieved positive operating cash flow of $11.9M. Management emphasized the therapy's 51% complete response rate and competitive advantages while preparing for upcoming competition from Inovio. The company is pursuing redosing trials, pediatric development, and international expansion opportunities.
Precigen (PGEN) reported Q3 2026 earnings of $0.08 per share, missing the consensus estimate of $0.09, though revenues of $74.15 million exceeded expectations. The stock has outperformed the S&P 500 by 15% year-to-date and holds a Zacks Rank #3 (Hold) rating. Monte Rosa Therapeutics (GLUE) is expected to report a quarterly loss of $0.10 per share with revenues projected at $45.33 million.
Precigen is set to report Q3 2026 earnings on Nov. 4 with expected revenues of $75.4 million and EPS of 9 cents. The company's sole marketed drug Papzimeos has shown strong sales momentum, but faces new competitive pressure following FDA approval of Inovio's Voceryq for the same indication (RRP). Precigen's stock fell ~20% following the competitive approval. The company's earnings surprise model does not predict a beat this quarter.
Zacks Research showcased strong performance across its various investment portfolios and rating systems during the week ended October 2, 2026. Multiple stocks received upgrades and delivered significant gains, including CRCT and PGEN surging 32% and 30.8% respectively following recommendation upgrades. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while the Focus List portfolio returned 19.86% versus 13.14% for the S&P 500 through August 31, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.